Table 2 Patient demographics, clinical characteristics and prior treatments among non-infected and infected patients
Non-infected (n = 40) | Infected (n = 12) | P value | |
|---|---|---|---|
Age | 63.7 ± 7.6 | 69.9 ± 6.9 | 0.02 |
Male, n (%) | 23 (57.5) | 11 (91.7) | 0.04 |
Smoking status, n (%) | |||
Never | 0 (0) | 0 (0) | 0.7 |
Former | 31 (77.5) | 10 (83.3) | |
Current | 9 (22.5) | 2 (16.7) | |
Pack-years | 42.3 ± 20.0 | 47.8 ± 16.1 | 0.2 |
Comorbid conditions, n (%) | |||
Cardiovascular | 13 (32.5) | 6 (50) | 0.3 |
Hypertension | 15 (37.5) | 6 (50) | 0.4 |
Diabetes | 0 (0) | 0 (0) | 1 |
Gastroesophageal reflux | 14 (35) | 6 (50) | 0.3 |
Treatment, n (%) | |||
ICS | 22 (55) | 6 (50) | 0.5 |
LABA | 32 (80) | 8 (66.7) | 0.3 |
LAMA | 32 (80) | 11 (91.7) | 0.3 |
FEV1 (% pred) | 58 ± 169 | 61 ± 17 | 0.6 |
FVC (% pred) | 87 ± 16 | 76 ± 17 | 0.04 |
BMI (kg/m2) | 26.4 ± 4.8 | 26.0 ± 4.4 | 0.8 |
GOLD stage, n (%) | |||
A | 13 (32.5) | 6 (50) | 0.4 |
B | 8 (20) | 1 (8.3) | |
C | 9 (22.5) | 1 (8.3) | |
D | 10 (25) | 4 (33.4) | |
Prior exacerbations, n (%) | |||
0 | 16 (40) | 4 (33.3) | 0.9 |
1 | 8 (20) | 3 (25) | |
≥ 2 | 16 (40) | 5 (41.7) | |
Weeks from last exacerbation | 26.2 ± 18.9 | 27.3 ± 19.1 | 0.6 |
CAT questionnaire | 11.2 ± 6.5 | 10.5 ± 7.6 | 0.6 |